Literature DB >> 21561876

Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention.

Charlotte R Hedin1, Andrew J Stagg, Kevin Whelan, James O Lindsay.   

Abstract

Crohn's disease (CD) is an incurable intestinal disorder in which the loss of immune tolerance to the commensal gut microbiota leads to chronic inflammation. The reason this occurs in specific individuals is unclear; however, a genetic predisposition is fundamental and relatives of patients with CD are at significant risk of developing the disease. Knowledge relating to the genetic loci that predispose to CD is accumulating, which raises the possibility of disease prediction and prevention in susceptible populations. However, the genetic basis of CD is complex and genotyping alone is likely to be insufficient to predict disease risk accurately. Specific physiological abnormalities associated with CD, such as increased intestinal permeability and raised faecal calprotectin, are also abnormal in some relatives of patients with CD. The combination of genotypic factors and biomarkers of risk makes the development of models of disease prediction a realistic possibility. Furthermore, enhanced understanding of the genotype and phenotype of the at-risk state in relatives of patients with CD allows the earliest stages in the pathogenesis of CD to be investigated and may allow intervention to prevent disease onset. This article reviews current knowledge of the at-risk phenotype in relatives of patients with CD and focuses on the implications for the design of future studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21561876     DOI: 10.1136/gut.2011.238568

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  14 in total

1.  Colorectal cancer: CRC--all about microbial products and barrier function?

Authors:  Christian Jobin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-20       Impact factor: 46.802

2.  Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study.

Authors:  Ashwin N Ananthakrishnan; Leslie M Higuchi; Edward S Huang; Hamed Khalili; James M Richter; Charles S Fuchs; Andrew T Chan
Journal:  Ann Intern Med       Date:  2012-03-06       Impact factor: 25.391

Review 3.  The role of large pedigrees in an era of high-throughput sequencing.

Authors:  Ellen M Wijsman
Journal:  Hum Genet       Date:  2012-06-20       Impact factor: 4.132

4.  Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease.

Authors:  Neil E McCarthy; Charlotte R Hedin; Theodore J Sanders; Protima Amon; Inva Hoti; Ibrahim Ayada; Vidya Baji; Edward M Giles; Martha Wildemann; Zora Bashir; Kevin Whelan; Ian Sanderson; James O Lindsay; Andrew J Stagg
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

5.  The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease.

Authors:  Charlotte R Hedin; Christopher J van der Gast; Andrew J Stagg; James O Lindsay; Kevin Whelan
Journal:  Gut Microbes       Date:  2017-01-23

6.  Perioperative Blood Transfusion and Postoperative Outcome in Patients with Crohn's Disease Undergoing Primary Ileocolonic Resection in the "Biological Era".

Authors:  Yi Li; Luca Stocchi; Yuanyi Rui; Ganglei Liu; Emre Gorgun; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

7.  Human intestinal epithelial cells express interleukin-10 through Toll-like receptor 4-mediated epithelial-macrophage crosstalk.

Authors:  Jinhee Hyun; Laura Romero; Reldy Riveron; Claudia Flores; Saravana Kanagavelu; Kristina D Chung; Ana Alonso; John Sotolongo; Jose Ruiz; Armine Manukyan; Sally Chun; Gaurav Singh; Pedro Salas; Stephan R Targan; Masayuki Fukata
Journal:  J Innate Immun       Date:  2014-08-20       Impact factor: 7.349

8.  A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients.

Authors:  David L Sigalet; Dragan Kravarusic; Decker Butzner; Bolette Hartmann; Jens J Holst; Jon Meddings
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

9.  Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease.

Authors:  Fa-Ming Zhang; Hong-Gang Wang; Min Wang; Bo-Ta Cui; Zhi-Ning Fan; Guo-Zhong Ji
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

10.  The CARD8 p.C10X mutation associates with a low anti-glycans antibody response in patients with Crohn's disease.

Authors:  Francis Vasseur; Boualem Sendid; Franck Broly; Corinne Gower-Rousseau; Aurore Sarazin; Annie Standaert-Vitse; Jean-Frederic Colombel; Daniel Poulain; Thierry Jouault
Journal:  BMC Med Genet       Date:  2013-03-18       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.